UNSPSC 51411613: Buphenine hydrochloride

This classification denotes a beta-adrenergic agonist with the molecular formula C19H25NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EC69E3PW7E, chemically known as benzyl alcohol, p-hydroxy-alpha-(1-((1-methyl-3-phenylpropyl)amino)ethyl)- but more generally known as buphenine hydrochloride, which bears US NIH Compound Identifier 4567. European Medicines Agency schedules Buphenine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00901MIG.

Most nations, for tariff and trade purposes, schedule buphenine hydrochloride under HS 29225000. SMILES: CC(CCC1CCCCC1)NC(C)C(C2CCC(CC2)O)O.CL.

UNSPSC 51411613 Buphenine hydrochloride is a Commodity code encompassing pharmaceutical active ingredients and finished medications sourced by state and local health agencies, fire departments, and health benefit programs. Recent state and local solicitations under this code target emergency medical supplies, generic pharmaceutical inventories, and specialty pharmacy benefit programs serving public employees and vulnerable populations. The issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances administering pooled procurement on behalf of member states and localities. Work solicited includes supply contracts for emergency life support medications, generic multi-source pharmaceuticals and over-the-counter products for statewide distribution networks, and direct-to-manufacturer prescription fulfillment programs designed to reduce intermediary costs and improve supply chain efficiency.

Geographic activity spans Florida, Texas, and Minnesota with participation from Oregon through cooperative purchasing arrangements. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for advanced life support medications (labetalol, epinephrine, adenosine, and diltiazem) for Tampa Fire Rescue with a due date of April 8, 2026 and estimated contract value of $40,000, carrying a 5 percent SLBE bid discount; the contract offers one-year initial term with two optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, with responses due April 3, 2026, designed to gather market intelligence before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026; the contract term runs two years with optional extensions, and vendors must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with product availability required by May 15, 2026 and agreement effectiveness July 1, 2026.